CbdMD Receives Notice from NYSE American Regarding Continued Listing Standard

Charlotte, North Carolina–(Newsfile Corp. – January 3, 2025)

cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBD-PA), a leading CBD company and operator of cbdMD, Paw CBD, and ATRx Labs, received a notice from the NYSE American on December 31, 2024. The notice indicated that the company is not in compliance with an additional NYSE American continued listing standard.

Notice from NYSE American

The NYSE American letter stated that cbdMD is not in compliance with the continued listing standard outlined in Section 1003(a)(i) of the NYSE American Company Guide. This news has raised concerns about the company’s standing on the stock exchange and its future prospects.

Investors and stakeholders are closely monitoring the situation to see how cbdMD will address the issue and work towards regaining compliance with the NYSE American’s listing standards.

Impact on Individuals

For individual investors holding cbdMD stock, this news could potentially impact the value of their investment. It is important for investors to stay informed about the company’s actions and decisions moving forward to make informed choices about their holdings.

Global Implications

As a prominent player in the CBD industry, cbdMD’s compliance issues with the NYSE American could have wider implications for the global market. Industry analysts and competitors are watching closely to see how this situation unfolds and what it might mean for the overall CBD sector.

Conclusion

cbdMD’s receipt of a notice from the NYSE American regarding its continued listing standard is a significant development that has implications for both individual investors and the global CBD market. It remains to be seen how the company will address the issue and whether it will be able to regain compliance with the NYSE American’s standards.